Drug Profile
ALT 801
Alternative Names: 264scTCR/IL-2; ALT-801; STAR™-CkLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Altor BioScience Corporation
- Developer Altor BioScience Corporation; Florida Department of Health; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Interleukins; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Bladder cancer; Multiple myeloma; Urogenital cancer
- No development reported Acute myeloid leukaemia; Malignant melanoma
Most Recent Events
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
- 27 Aug 2019 NantKwest withdraws phase Ib/II trial in Merkel cell carcinoma (Combination therapy, Second-line therapy or greater) in August 2019 (NCT03167164)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)